Clinical Trials
Novel Approach
Most drugs, including for the treatment of cancer, are not able to enter the brain because of the blood-brain barrier. Learn more about the blood-brain barrier and the LRP-directed peptide-drug conjugate approach to targeting tumors in the brain.
Learn more
GRN1005 Against Brain Metastases from Lung Cancer (GRABM-L)
Helpful Information
- Whole Brain Radiation Therapy is commonly used to irradiate visible tumors in the brain along with very small tumor deposits which are often undetectable.
- The objective response rate measures how many patients in the study have had either a partial or complete response to treatment.
- Intra-cranial disease is cancer that is present inside the brain or cranial compartment.
- Extra-cranial disease is cancer that is present outside the brain.
- Progression-free survival (PFS) is the length of time during and after treatment in which the cancer does not get worse.
- Duration of overall objective response is the length of time of the response.
A Phase 2, Multi-Center, Open-Label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients with Brain Metastases
Geron is conducting a clinical trial to study the effect of our product candidate, GRN1005, in patients whose non-small cell lung cancer (NSCLC) has metastasized to the brain. This study is open to patients with metastatic NSCLC who may or may not have had prior Whole Brain Radiation Therapy (WBRT).
In this Phase 2 clinical trial, our clinical researchers and investigators are evaluating how GRN1005 may impact overall objective response rates in both intra-cranial and extra-cranial disease.
In addition to understanding the impact of GRN1005, we will determine progression-free survival (PFS) and obtain data on the duration of overall objective response.
GRN1005 is an investigational treatment for cancer in development by Geron and has not been approved by the FDA or any other regulatory agency.
About GRN1005
Most drugs, including for the treatment of cancer, are not able to enter the brain because of the blood-brain barrier (BBB). This presents a challenge for treating cancer in the brain. GRN1005 is designed to deliver paclitaxel, an effective anti-cancer agent, across the BBB and into brain tumors by exploiting a native mechanism by which essential substances, such as lipids and hormones, successfully enter the brain. Learn more
Cancer Definitions
To learn more about the terms and definitions used in cancer clinical studies you may find the National Cancer Institute Dictionary of Cancer Terms a useful resource.
Para obtener más información acerca de los términos y las definiciones utilizadas en los estudios clínicos sobre el cáncer es posible que el Instituto Nacional del Cáncer Diccionario de Cáncer en un recurso útil.
How to Participate
To learn more about how to participate in this clinical trial, please visit ClincialTrials.gov for the full trial summary and enrollment criteria.
Additionally, patients or their physicians may directly contact the nearest trial center for more information about how to participate. The study is currently being conducted in multiple trial centers across the United States.
Novel Approach
Most drugs, including for the treatment of cancer, are not able to enter the brain because of the blood-brain barrier. Learn more about the blood-brain barrier and the LRP-directed peptide-drug conjugate approach to targeting tumors in the brain.
Learn more
